WellMedr review

Take a quarter dose of tirzepatide here and you pay what a full dose costs — the plan card says "Same price regardless of dosage" in as many words. On semaglutide it says nothing either way, so there the answer is simply unknown. Give WellMedr real credit for the thing most of this category won't do: it treats microdosing as a product line rather than a discount, publishes eight low-dose SKUs, and prints what is in each one. Its safety notice is blunt and sits where you can find it, and it names the clinical group treating you instead of gesturing at "licensed providers". Three things will cost you if you misread them. The rate on the plan card is a twelve-month commitment; the banner says so, and month to month has no published rate at all. A month here is four weeks, so the year is thirteen charges. And the same page that sells you a low dose headlines "ZERO Side Effects" — for a compounded GLP-1, that claim is doing marketing work, not medical work.

Vs median

$110/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

WellMedr dispenses through a Mycelium Pharmacy facility. No bloodwork is required before you start. A clinician review is included in the price.

WellMedr is a direct-to-consumer telehealth brand selling compounded semaglutide and compounded tirzepatide alongside brand-name Ozempic and Zepbound, with a separately merchandised low-dose line of eight microdose products — four oral, four injectable — each combining a GLP-1 with NAD+, B12, L-carnitine, inositol, magnesium or L-theanine. Care coaching with a certified medical assistant is bundled into every plan. The clinical layer is contracted rather than in-house: its telehealth consent names OpenLoop Health, Inc. and the OpenLoop Healthcare Partners professional corporations as the treating practice. Prices are set after the medical intake, and the storefront carries no purchasable figure for any GLP-1 product.

"ZERO SIDE EFFECTS" HEADLINES THE MICRODOSE PAGE, under the subhead "Zero side effct for 70%+ of members" — the typo is theirs. An unqualified zero-side-effect claim for a compounded GLP-1 is not something any evidence supports, and it sits directly above the safety notice that warns about thyroid tumors

• ONE PRICE AT EVERY DOSE ON THE TIRZEPATIDE PLAN. A patient deliberately holding a quarter dose pays what a full-dose patient pays. WellMedr is candid about it, and candour does not change the arithmetic
• ITS FAQ SAYS THE MEDICATIONS ARE FDA APPROVED. Asked "Are these medications FDA approved?", the page answers "Yes. We only work with U.S. licensed pharmacies that dispense FDA-approved medications" — while the footer of that same page says they are "not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality". A buyer asking the one regulatory question that matters is told the opposite of the truth
• TWO DIFFERENT BILLING CYCLES ARE PUBLISHED. The plan cards say "shipped every 4 weeks" — 13 charges a year — while the refund policy says the subscription "will automatically renew every 21 days", which is about 17. Which one your card sees is not knowable from the site
• THE ADVERTISED $59 IS A TWELVE-MONTH RATE. The banner reads "Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life", so the semaglutide figure a reader sees first is not available month to month. It names only that one figure — the $99 tirzepatide card carries no such condition and says "Cancel or change anytime" — and yet no standing month-to-month rate is published for either molecule
• A "MONTH" HERE IS FOUR WEEKS. Both plans ship every 4 weeks, which is 13 charges a year rather than 12 — roughly 8.6% more than the monthly label implies
• No standing month-to-month rate is published anywhere. Both "Check Eligibility" buttons lead to a checkout app that will not load without a plan parameter, so the recurring figure is only visible after a medical intake
• Six of the eight microdose SKUs publish no price at all, and the two that do publish the same $199/month regardless of which formulation you pick
• The semaglutide plan makes no statement about dose basis in either direction, so whether a low dose costs less there is simply unknown
• Two discounts stack — "$200 OFF Every Month" and a separate "$150 off for Life" new-customer offer — and neither can be reversed into a standing rate from the open site
• The results carousel is disclosed as "Inspired by real patient success stories in similar Telehealth programs", so the named before-and-after figures are not WellMedr patients
• The top bar advertises "FDA-regulated pharmacies", which is a claim about the pharmacy and not the drug — the compounded medication itself is not FDA-approved
• Leans hard on celebrity endorsement — Dr. Nowzaradan, Kevin O'Leary, Russell Wilson, Ray Lewis, Lexi Thompson, Christina Milian
• The dispensing pharmacy is named only in the privacy policy — nowhere on the pricing page, the microdose page or the FAQ, which say only "accredited U.S. pharmacies" and "US-Certified Pharmacy"
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

WellMedr is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• Low dose vs full dose
• What a flat price costs at a low dose
• The true annual cost of a plan